| Date | Title | Description | Source |
| 07.02.2023 | Investor Syncona blames bear market's ravaging of British bi... | Life sciences investment firm Syncona has blamed a “disappointing” drop in returns on plummeting sha... | fiercebiot... |
| 24.10.2022 | Syncona To Buy Applied Genetic Technologies, for Up to $73.5... | A newly established portfolio company of Syncona Limited (LON: SYNC), a London, UK-based healthcare ... | finsmes.co... |
| 15.07.2022 | Former Spark exec to lead a gene therapy upstart of his... | Joseph La Barge
→ Dave Greenwald’s days as acting CEO of Apertura Gene Therapy are over as Jos... | endpts.com... |
| 18.02.2022 | Amgen, Ipsen vet moves up the ladder with Coherus' anti-PD-1... | Paul Reider
After decades in the biopharma industry, Paul Reider is now in his first C-suite role as... | endpts.com... |
| 04.02.2022 | Syncona : Freeline Announces Inducement Grants Under Nasdaq ... | LONDON, February 3, 2022 - Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company"... | marketscre... |
| 10.01.2022 | Syncona : Autolus announces 2022 priorities | obe-cel has the potential to transform outcomes for adult ALL patients
Phase 2 FELIX study data expe... | marketscre... |
| 07.01.2022 | Syncona : Freeline Announces Inducement Grants Under Nasdaq ... | LONDON, January 6, 2022 - Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company"... | marketscre... |
| 06.01.2022 | Syncona : Freeline Announces FDA Clearance of Investigationa... | FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1
FLT201 P... | marketscre... |
| 16.12.2021 | Anaveon raises CHF 110 million | | startuptic... |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubs... | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity ... | marketscre... |
| 12.11.2021 | Anaveon announces poster presentation at the 2021 Society fo... | ANV419 demonstrates highly promising safety profile
November 12, 2021 - Anaveon, a clinical stage, i... | marketscre... |
| 11.11.2021 | Syncona Interim Results for the period ending 30 September 2... | 11 November 2021
Syncona Limited
Interim Results for the six months ended 30 September 2021
Continue... | marketscre... |
| 11.11.2021 | Syncona Interim Results for the six months ended 30 Septembe... | Continued focus on hands-on engagement with a maturing portfolio with key milestones ahead
Syncona L... | marketscre... |
| 27.10.2021 | Quell Therapeutics Granted CTA Approval to Begin First Clini... | First clinical trial will investigate QEL-001 as a novel treatment to prevent organ rejection in liv... | marketscre... |
| 24.09.2021 | Syncona : Quell Therapeutics Significantly Expands Clinical ... | Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell's... | marketscre... |
| 02.09.2021 | Syncona : Purespring strengthens senior leadership with appo... | Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of ... | marketscre... |
| 17.08.2021 | Syncona : announces First Quarter Update | We are pleased with the continued positive clinical progress across our companies over the period, w... | marketscre... |
| 17.08.2021 | Syncona : Quarterly Update covering the period from 31 March... | Syncona Limited
First Quarter Update
17 August 2021
Syncona Ltd, a leading healthcare company focuse... | marketscre... |
| 22.07.2021 | Syncona : Quell Therapeutics Appoints Dominik Hartl, M.D., a... | Dr. Hartl, former Therapeutic Area Head - Autoimmunity/Transplantation/Inflammation at Novartis Inst... | marketscre... |
| 28.06.2021 | Globus Maritime Limited : Announces Pricing of $50 Million R... | GLYFADA - Globus Maritime Limited (the 'Company' or 'Globus') (NASDAQ: GLBS) announced today that it... | marketscre... |
| 17.06.2021 | Syncona : Final Results for the Year Ended 31 March 2021 | Good progress despite challenging backdrop with positive momentum across an expanded portfolio of 11... | marketscre... |
| 17.06.2021 | Syncona : Final Results for the period ending 31 March 2021 | 17th June 2021
Syncona Limited
Final Results for the Year Ended 31 March 2021
Good progress despite ... | marketscre... |
| 17.06.2021 | SYNCONA LIMITED
Syncona : Final Results for the Year Ended ... | Good progress despite challenging backdrop with positive momentum across an expanded portfolio of 11... | marketscre... |
| 17.06.2021 | SYNCONA LIMITED
Syncona : Final Results for the period endi... | 17th June 2021
Syncona Limited
Final Results for the Year Ended 31 March 2021
Good progress despite ... | marketscre... |
| 04.05.2021 | SYNCONA LIMITED
Syncona : Achilles Corporate Presentation -... | Achilles Therapeutics
Precision T cell therapies to treat solid tumors
May 2021
non-confidential © A... | marketscre... |
| 04.05.2021 | Syncona : Achilles Corporate Presentation - May 2021 | Achilles Therapeutics
Precision T cell therapies to treat solid tumors
May 2021
non-confidential © A... | marketscre... |
| 20.04.2021 | GEOPARK LIMITED
GeoPark Limited : Announces the Successful ... | GeoPark Limited (“GeoPark” or the “Company”) (NYSE: GPRK), an exempted company incorporated under th... | marketscre... |
| 16.04.2021 | Novavax CFO Greg Covino makes a quick exit as leadershi... | Greg Covino
→ If it seems like Covid-19 vaccine bridesmaid Novavax is shuttling staffers in and... | endpts.com... |
| 06.04.2021 | GEOPARK LIMITED
GeoPark Limited : Announces Tender Offer fo... | GeoPark Limited (“GeoPark” or the “Company”) (NYSE: “GPRK”), an exempted company incorporated under ... | marketscre... |
| 01.04.2021 | SYNCONA LIMITED
Syncona : Autolus Therapeutics Receives PRI... | 'We are pleased to have received PRIME designation for AUTO1 as it will accelerate the review of a p... | marketscre... |
| 25.03.2021 | SYNCONA LIMITED
Syncona : Anaveon receives CTA approval to ... | Anaveon, a clinical stage, immuno-oncology company, today announced that its Clinical Trial Applicat... | marketscre... |
| 08.01.2021 | Alkermes promotes from within to find new CFO and COO in... | Iain Brown
→ Vowing to find a groove after a string of bogeys on the scorecard, Richard Pops has... | endpts.com... |
| 19.11.2020 | SYNCONA LIMITED
Syncona : Achilles Therapeutics Raises £52.... | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalis... | marketscre... |
| 19.11.2020 | Syncona : Achilles Therapeutics Raises £52.7 Million in an O... | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalis... | marketscre... |
| 16.09.2020 | SYNCONA LIMITED
Syncona : Neogene Therapeutics Raises $110 ... | Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of ful... | marketscre... |
| 31.07.2020 | Tetraphase deal done, La Jolla Pharmaceutical taps Lar... | Larry Edwards
→ As La Jolla Pharmaceutical closed on their acquisition of Tetraphase on We... | endpts.com... |
| 08.04.2020 | Keytruda nabs another priority review; Quell ties up ... | → Add another priority review for Merck’s Keytruda. Unlike most FDA submissions, this one... | endpts.com... |
| 23.03.2020 | VC shop Syncona warns of company trial delays as COVID-19 pa... | Life science venture capital firm Syncona is warning of serious delays to studies across its biotech... | fiercebiot... |
| 23.03.2020 | VC shop Syncona warns of company trial delays as COVID-19 pa... | Life science venture capital firm Syncona is warning of serious delays to studies across its biotech... | fiercebiot... |
| 14.06.2019 | Tariq Kassum jumps from Obsidian to Celsius helm; Quell... | Tariq Kassum Linkedin
→ Cambridge, Massachusetts-based Celsius Therapeutics — which was lau... | endpts.com... |
| 20.05.2019 | UCLTF completes £1m investment into Quell Therapeutics as pa... | Syncona announces the foundation of Quell Therapeutics, a new cell therapy company, with a £35 milli... | ucltf.co.u... |
| 27.02.2019 | UZH spinoff secures CHF 35 million Series A financing | | startuptic... |
| 26.02.2019 | Amicus blueprints growth plans for Philly-based gene ther... | → As Roche puts down its foot in Philadelphia as the base for its budding gene therapy operat... | endpts.com... |
| 06.07.2017 | UK-based biotech firm Nightstar raises $45 million Series C | London-based Nightstar, a company that develops treatments for retinal diseases, raised $45 million ... | tech.eu/br... |